Clinical Trials Sponsored by ISU Abxis Co., Ltd.

Total 12 results

ISU Abxis Co., Ltd.

Active, not recruiting

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of
ISU Abxis Co., Ltd.

Completed

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Gaucher Disease

Australia
ISU Abxis Co., Ltd.

Completed

Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

Gaucher Disease, Type 1
ISU Abxis Co., Ltd.

Withdrawn

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

Gaucher Disease
ISU Abxis Co., Ltd.

Completed

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

Gaucher Disease
ISU Abxis Co., Ltd.

Recruiting

Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Fabry Disease

Korea, Republic of
ISU Abxis Co., Ltd.

Unknown

Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients

Acute Myocardial Infarction

Korea, Republic of
ISU Abxis Co., Ltd.

Completed

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

Gaucher Disease
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of
Shanghai Mental Health Center
Su Zhou YiHua Biotechnology Co. LTD

Completed

Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb

Major Depressive Disorder

China
Shanghai Mental Health Center
Su Zhou YiHua Biotechnology Co. LTD

Unknown

Comparison of Anyu Peibo With Placebo in Treatment of MDD in China

Major Depressive Disorder

China
Shanghai Mental Health Center
Su Zhou YiHua Biotechnology Co. LTD

Completed

Comparison of Anyu Peibo With Placebo in Treatment of MDD

Major Depressive Disorder (MDD)

China

3

Subscribe